Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 août 2024 16h05 HE
|
Fractyl Health, Inc.
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
08 août 2024 08h00 HE
|
Fractyl Health, Inc.
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
07 août 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
30 juil. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
25 juin 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
24 juin 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
23 juin 2024 13h30 HE
|
Fractyl Health, Inc.
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Platform at ADA 2024.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
29 mai 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
20 mai 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
08 mai 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference